GTS-21 HCl – (156223-05-1)

GTS-21, also known as DMXBA or DMBX-anabaseine, is a synthetic derivative of the natural product anabaseine. It acts as a partial agonist at neural nicotinic acetylcholine receptors (nAChRs), specifically targeting the α7 subtype.

GTS-21 has been studied for its potential therapeutic uses, particularly in enhancing memory and cognitive function, and in treating neurodegenerative diseases such as Alzheimer’s disease, as well as psychiatric disorders like schizophrenia. It has also shown anti-inflammatory and neuroprotective effects in animal models.

Clinical trials have explored its efficacy in improving cognitive function and sensory gating in schizophrenia patients, though some trials were discontinued. GTS-21 is also being investigated for its role in reducing inflammation in conditions like rheumatoid arthritis and its potential benefits in critical illness-related muscle atrophy.

The drug is metabolized via O-demethylation and glucuronidation, primarily involving CYP1A2 and CYP2E1 enzymes.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/GTS-21
https://www.medchemexpress.com/gts-21.html
https://www.medkoo.com/products/18798
https://go.drugbank.com/drugs/DB05708
https://pubmed.ncbi.nlm.nih.gov/30006848/